Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

• Status: Completed
• Trial end date: 2013-07-22

Summary

The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily, umeclidinium bromide (125mcg) once-daily to fluticanse propionate/salmeterol (250/50mcg) twice-daily versus placebo to fluticanse propionate/salmeterol (250/50mcg) twice-daily on lung function, COPD-related health status assessments and safety in COPD subjects.

• Phase: Phase 3

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Bromides; Fluticasone; Fluticasone Propionate, Salmeterol Xinafoate Drug Combination; Muscarinic Antagonists; Salmeterol Xinafoate; Xhance